Exeltis Pharmaceuticals Holding, S.L. Sustainability Profile
Exeltis Pharmaceuticals Holding, S.L., commonly referred to as Exeltis, is a prominent player in the global pharmaceutical industry, headquartered in Spain. Founded in 2015, the company has rapidly expanded its operations across Europe, Latin America, and other key regions, focusing on innovative healthcare solutions. Specialising in women's health, dermatology, and other therapeutic areas, Exeltis is recognised for its commitment to developing unique products that address unmet medical needs. The company’s portfolio includes a range of prescription medications and over-the-counter products, distinguished by their efficacy and safety profiles. With a strong market presence, Exeltis has achieved significant milestones, including strategic partnerships and a growing international footprint, positioning itself as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Exeltis Pharmaceuticals Holding, S.L.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Exeltis Pharmaceuticals Holding, S.L.'s score of 18 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Exeltis Pharmaceuticals Holding, S.L.'s reported carbon emissions
Exeltis Pharmaceuticals Holding, S.L., headquartered in Spain, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Exeltis may not have established formal commitments to reduce carbon emissions or may not publicly disclose such information. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to align with global climate goals. However, without specific emissions data or commitments from Exeltis, it is unclear how the company is addressing its environmental impact or contributing to broader industry efforts in climate change mitigation.
How Carbon Intensive is Exeltis Pharmaceuticals Holding, S.L.'s Industry?
How Carbon Intensive is Exeltis Pharmaceuticals Holding, S.L.'s Location?
Exeltis Pharmaceuticals Holding, S.L.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Exeltis Pharmaceuticals Holding, S.L. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
